ALKB On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
Berlin
OTC US

alk-abello a/s (ALKB) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALK-ABELLO A/S (ALKB)
\

Related News

No related news articles were found.

alk-abello a/s (ALKB) Related Businessweek News

No Related Businessweek News Found

alk-abello a/s (ALKB) Details

ALK-Abelló A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, as well as sublingual drops and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company markets its products primarily under the ACARIZAX/ODACTRA, MITICURE, RAGWITEK, GRAZAX/GRASTEK, and CEDARCURE brand names. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

2,379 Employees
Last Reported Date: 05/9/19
Founded in 1923

alk-abello a/s (ALKB) Top Compensated Officers

Senior CMC Project Manager & Director
Total Annual Compensation: kr275.0K
Compensation as of Fiscal Year 2018.
alk-abello a/s
ALK-Abelló A/S Announces Unaudited Earnings Results for the First Quarter of 2019; Provides Earnings Guidance for the Full Year 2019

ALK-Abelló A/S announced unaudited earnings results for the first quarter of 2019. For the quarter, the company reported revenue of DKK 867 million compared to DKK 752 million a year ago. Operating profit was DKK 133 million compared to DKK 92 million a year ago. For the full year 2019, revenue is projected to be DKK 3,100 million - DKK 3,300 million, operating profit is expected at DKK 100 million - DKK 200 million.

ALK-Abelló A/S, Q1 2019 Earnings Call, May 09, 2019

ALK-Abelló A/S, Q1 2019 Earnings Call, May 09, 2019

New Data Shows Alk’s House Dust Mite Slit-Tablet Significantly Improves Quality of Sleep for Allergic Rhinitis Patients

ALK has released new analysis of clinical trial data showing that its sublingual allergy immunotherapy (SLIT) tablet for the treatment of house dust mite (HDM)-related allergy can significantly improve quality of sleep for allergic rhinitis patients. The results were presented for the first time on 25 February 2019 as a scientific poster at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, California, and were gathered during a post-hoc analysis of data from the MERIT Phase III clinical trial to evaluate the efficacy and safety of the HDM SLIT-tablet in the treatment of allergic rhinitis. Sleep issues are common in patients with uncontrolled allergic rhinitis, with one study reporting that 24% have difficulty falling asleep, 26% lack a good night's sleep, and 31% have difficulty staying asleep. Another study reported that almost 74% of adults with HDM-induced allergic rhinitis had consulted a doctor about the impact of their allergy on their sleep and concluded that sleep disorders were high in frequency and significant in their impact.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ALKB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALKB.
View Industry Companies
 

Industry Analysis

ALKB

Industry Average

Valuation ALKB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.5x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ALK-ABELLO A/S, please visit www.alk.net. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.